Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer
- 1 March 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 203 (3), 537-545
- https://doi.org/10.1097/ju.0000000000000531
Abstract
Purpose: Prospective validation of gallium-68 ( 68Ga) prostate specific membrane antigen (PSMA)-PET/CT in initial staging of prostate cancer is lacking. This study evaluates diagnostic accuracy of 68Ga-PSMA-PET/CT in detection of lymph node metastases in patients with intermediate-high risk prostate cancer. Materials and Methods: From October 2017 to October 2018, newly diagnosed prostate cancer patients with negative bone scan and >10% MSKCC risk of lymph node metastases were prospectively included. In candidates for extended pelvic lymph node dissection, 68Ga-PSMA-PET/CT prior to planned surgery was performed. Scan results were evaluated in a second tumor board meeting to assess potential change of management. Sensitivity, specificity, positive and negative predictive value for the detection of lymph node metastases were calculated per patient and per resection template using histopathology as a reference. PET-based change of management was also reported. Results: A total of 103 patients were eligible for analysis. Ninety-seven extended pelvic lymph node dissections were performed. Forty-one patients (42.3%) had 85 lymph node metastases. Seventeen patients were PET-positive, resulting in a patient-based sensitivity of 41.5% (95% CI: 26.7%-57.8%) for the detection of lymph node metastases. Patient-based specificity was 90.9% (95% CI: 79.3%-96.6%), positive predictive value was 77.3% (95% CI: 54.2%-91.3%) and negative predictive value was 67.6% (95% CI: 55.6%-77.7%). PET-based change of management was observed in 13 patients (12.6%). Conclusions: In newly diagnosed prostate cancer patients with >10% MSKCC risk of lymph node involvement, 68Ga-PSMA-PET/CT detects lymph node metastases with high specificity and moderate sensitivity; this leads to change of management in 12.6% of patients.Keywords
This publication has 20 references indexed in Scilit:
- 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate CancerEuropean Urology, 2016
- Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate CancerJournal of Urology, 2015
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2014
- Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node–Positive Prostate Cancer: A Systematic Review of the LiteratureEuropean Urology, 2013
- Complications of Pelvic Lymph Node Dissection for Prostate CancerCurrent Urology Reports, 2011
- MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort studyThe Lancet Oncology, 2008
- Complications and Other Surgical Outcomes Associated with Extended Pelvic Lymphadenectomy in Men with Localized Prostate CancerEuropean Urology, 2006
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- A Preoperative Nomogram Identifying Decreased Risk of Positive Pelvic Lymph Nodes in Patients With Prostate CancerJournal of Urology, 2003